NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram(cEEG) and stereoelectrocencephalography(sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders.

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.03 by 133.33 percent. This is a 138.89 percent increase over losses of $(0.18) per share from the same period last year.

Earnings

News

EQT Q2 EPS $0.07 Beats $0.03 Estimate

Guidance

UPDATE: Kraton Raises FY21 Adj. EBITDA Guidance To $280M-$300M

Shares of MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) were flat in after-market trading after the company reported Q2 results.
<h2>Quarterly Results</h2>
Earnings per share were up 55.00% year over year to $1.24, which beat the estimate of $0.95.
Revenue of $649,573,000 up by 26.61% from the same period last year, which beat the estimate of $561,200,000.
<h2>Outlook</h2>
Earnings guidance hasn&#39;t been issued by the company for now.
MYR Group hasn&#39;t issued any revenue guidance for the time being.
<h2>Recent Stock Performance</h2>
Company&#39;s 52-week high was at $97.75
52-week low: $31.27
Price action over last quarter: Up 20.30%
<h2>Company Overview</h2>
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution network and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.

MYRG

MYR Group: Q2 Earnings Insights

Kraton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRA#NYSE">KRA</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.50 by 36 percent. This is a 6.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $493.62 million which beat the analyst consensus estimate of $427.84 million by 15.38 percent. This is a 38.78 percent increase over sales of $355.68 million the same period last year.

Kraton Q2 Adj. EPS $0.32 Misses $0.50 Estimate, Sales $493.62M Beat $427.84M Estimate; Raises FY21 Guidance

First US Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSB#NASDAQ">FUSB</a>) reported quarterly earnings of $0.14 per share. This is a 133.33 percent increase over earnings of $0.06 per share from the same period last year.

FUSB

First US Bancshares Q2 EPS $0.14 Up From $0.06 YoY

Shares of Meta Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) were flat in after-market trading after the company reported Q3 results.
<h2>Quarterly Results</h2>
Earnings per share rose 128.30% over the past year to $1.21, which beat the estimate of $0.93.
Revenue of $130,928,000 higher by 26.89% from the same period last year, which beat the estimate of $116,650,000.
<h2>Looking Ahead</h2>
Earnings guidance hasn&#39;t been issued by the company for now.
Meta Financial Group hasn&#39;t issued any revenue guidance for the time being.
<h2>How To Listen To The Conference Call</h2>
Date: Jul 28, 2021
Time: 05:00 PM
ET Webcast URL: <a href="https://edge.media-server.com/mmc/p/6d3dj2dr" title="https://edge.media-server.com/mmc/p/6d3dj2dr">https://edge.media-server.com/mmc/p/6d3dj2dr</a>
<h2>Recent Stock Performance</h2>
Company&#39;s 52-week high was at $54.65
52-week low: $17.74
Price action over last quarter: down 1.99%
<h2>Company Description</h2>
Meta Financial Group Inc is a unitary savings and loan holding company. It&#39;s a wholly-owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves and a payments company providing services on a nationwide basis. Meta has three business segments: Consumer, Commercial and Corporate Services/Other.

CASH

Recap: Meta Financial Group Q3 Earnings

MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $0.95 by 30.53 percent. This is a 55 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $649.57 million which beat the analyst consensus estimate of $561.20 million by 15.75 percent. This is a 26.61 percent increase over sales of $513.05 million the same period last year.

MYR Group Q2 EPS $1.24 Beats $0.95 Estimate, Sales $649.57M Beat $561.20M Estimate

QCOM

Qualcomm Says In Spite Of Having Great Results, Both Revenue, EPS, All Exceeding Right End Of Our Guidance, Says Still Have Demand Outpacing Supply

UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) reported quarterly earnings of $0.44 per share. This is a 13.73 percent decrease over earnings of $0.51 per share from the same period last year.

UDR Q2 Adj. FFO $0.44 Down From $0.51 YoY; Raises FY21 Guidance

Offerings

Infrastructure and Energy Alternatives, Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants; No Size Disclosed

Third quarter sales are expected to be in a range of $515 million to $545 million, with PowerA contributing $55 million to $65 million. Adjusted earnings per share are expected to be in a range of $0.30 to $0.35. The outlook includes a favorable foreign exchange impact of 2 percent on sales and $0.01 on adjusted earnings per share.
For the full year, sales are expected to be in a range of $2.0 billion to $2.07 billion, with PowerA contributing $255 million to $275 million. Adjusted earnings per share are expected to be in a range of $1.35 to $1.45. The outlook includes a favorable foreign exchange impact of 3 percent on sales and $0.05 on adjusted earnings per share.

ACCO

ACCO Brands Sees Q3 Adj. EPS $0.30-$0.35 vs $0.36 Est., Sales $515M-$545M vs $514.9M Est.; Sees FY21 Adj. EPS $1.35-$1.45 vs $1.22 Est., Sales $2B-$2.07B vs $1.96B Est.

WIIM

MKSI

MKS Instruments shares are trading lower after the company reported Q2 earnings results and issued Q3 guidance.

Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) reported quarterly earnings of $2.54 per share. This is a 90.98 percent increase over earnings of $1.33 per share from the same period last year.

Northeast Bank Q4 EPS $2.54 Up From $1.33 YoY

Shares of Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) rose&nbsp;in after-market trading after the company reported Q2 results.
<h2>Quarterly Results</h2>
Earnings per share rose 20.73% over the past year to $0.99, which beat the estimate of $0.96.
Revenue of $4,585,000,000 up by 14.62% year over year, which beat the estimate of $4,440,000,000.
<h2>Outlook</h2>
The upcoming fiscal year&#39;s EPS expected to be between $4.00 and $4.06.
The upcoming fiscal year&#39;s revenue expected to be between $18,400,000,000 and $18,500,000,000.
<h2>Conference Call Details</h2>
Date: Jul 28, 2021
Time: 05:00 PM
ET Webcast URL: <a href="https://www.webcaster4.com/Webcast/Page/990/42041" title="https://www.webcaster4.com/Webcast/Page/990/42041">https://www.webcaster4.com/Webcast/Page/990/42041</a>
<h2>Technicals</h2>
52-week high: $82.73
52-week low: $61.29
Price action over last quarter: down 0.83%
<h2>Company Description</h2>
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world&#39;s largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company&#39;s headquarters are in Teaneck, New Jersey.

CTSH

Cognizant Tech Solns: Q2 Earnings Insights

Facebook CEO Says Video Accounts For Almost Half Of All Time Spent On Facebook, Says Reels Is Largest Contributor To Engagement Growth On Instagram

IRBT

iRobot shares are trading lower after the company reported worse-than-expected Q2 EPS results and cut FY21 guidance.

Buybacks

RenaissanceRe Renews Buyback Plan

Shares of Xilinx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLNX#NASDAQ">XLNX</a>) were flat in after-market trading after the company reported Q1 results.
<h2>Quarterly Results</h2>
Earnings per share rose 150.00% year over year to $0.95, which beat the estimate of $0.77.
Revenue of $878,606,000 rose by 20.91% from the same period last year, which beat the estimate of $856,690,000.
<h2>Outlook</h2>
Xilinx hasn&#39;t issued any earnings guidance for the time being.
Xilinx hasn&#39;t issued any revenue guidance for the time being.
<h2>How To Listen To The Conference Call</h2>
Date: Jul 28, 2021
Time: 04:30 PM
ET Webcast URL: <a href="https://investor.xilinx.com/events/event-details/q1-fiscal-year-2022-financial-press-release-scheduled-distribution-no" title="https://investor.xilinx.com/events/event-details/q1-fiscal-year-2022-financial-press-release-scheduled-distribution-no">https://investor.xilinx.com/events/event-details/q1-fiscal-year-2022-financial-press-release-scheduled-distribution-no</a>
<h2>Recent Stock Performance</h2>
52-week high: $154.93
52-week low: $96.71
Price action over last quarter: Up 13.82%
<h2>Company Profile</h2>
Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets. Xilinx designs and sells chips, but it outsources manufacturing to third-party chip foundries such as TSMC.

XLNX

Recap: Xilinx Q1 Earnings

Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) reported quarterly earnings of $2.33 per share. This is a 90.98 percent increase over earnings of $1.22 per share from the same period last year.

Hartford Finl Servs Gr Q2 EPS $2.33 Up From $1.22 YoY

ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.26 by 65.38 percent. This is a 258.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $517.80 million which beat the analyst consensus estimate of $474.16 million by 9.20 percent. This is a 41.13 percent increase over sales of $366.90 million the same period last year.

ACCO Brands Q2 Adj. EPS $0.43 Beats $0.26 Estimate, Sales $517.80M Beat $474.16M Estimate

It's been an eventful year for NeuroOne Medical Technologies Corp (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The Minnesota- based company has announced the successful completion of its first performance milestone for its Zimmer Biomet Agreement and closed a $12.5 million private placement. 

NeuroOne, a cutting-edge electrode company, intends to use its product for medical conditions such as epilepsy, Parkinson's disease, back pain due to failed back surgery, and in the future for incontinence and hypertension. The devices are placed either through smaller incisions or percutaneously. The technology uses photolithography to ensure a consistent product using cost-efficient manufacturing methods. 

The company has successfully met the first performance milestone in a distribution and development agreement that was signed with Zimmer Biomet last summer. In addition to acquiring the exclusive global distribution rights to NeuroOne's Evo&#8482; (Evo) patented electrode technology, the partnership also offers the potential for NeuroOne to earn back-end milestone payments if certain events are met within a specified time frame. 

President and CEO of NeuroOne Dave Rosa said, "The company is quite pleased to meet this development milestone. Coupled with the announcement of our recent financing, we are confident that our partnership with Zimmer Biomet and the progress in our sEEG program position the company well to offer a unique full complement of brain recording diagnostic technology in 2021 and beyond." 

The Zimmer agreement is intended to allow NeuroOne to implement the proceeds in a proposed Nasdaq uplisting, acceleration of research and development efforts, a potential second commercial product launch in 2021 pending regulatory clearance, and other general corporate purposes. NeuroOne received FDA clearance for its Evo cortical technology in November 2019. The Evo Electrode is over 7 times thinner than a silicon electrode. The flexibility and reduced volume would reduce pain and edema.

The Evo's polyimide substrate has properties such as increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts. The single, thin tail design allows the implanted electrode tail to be tunneled through one incision, which should reduce infection risk and procedure time.

NeuroOne anticipates that the replacement of current silicone electrodes with polyimide substrate electrodes for the acquisition of intracranial electroencephalography (iEEG) could provide enhanced clinical electrophysiological value with reduced cost.

In partnership with the Mayo Clinic, Wisconsin Alumni Research Foundation (WARF), and other prominent academic medical centers, the company began developing its cortical electrode technology in 2015. NeuroOne initially focused its efforts on epilepsy and intraoperative tumor monitoring markets. The company intends to continue to develop the technology in therapeutic applications for Parkinson's disease, epilepsy, and pain management due to failed back surgery procedures.

Biotech

Penny Stocks

Emerging Markets

Health Care

Psychology

Small Business

Markets

Tech

General

NEUROONE BEGINS 2021 BY HITTING FIRST PERFORMANCE MILESTONE AND CLOSES LUCRATIVE PRIVATE PLACEMENT

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs May 25)

<ul>
	<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>)</li>
	<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) (<a href="https://www.benzinga.com/general/biotech/21/05/21275537/pieris-stock-surges-on-development-pact-with-genentech-for-respiratory-ophthalmology-settings">moved </a> on a R&amp;D pact with Roche Holdings AG (OTC: <a class="ticker" href="https://www.benzinga.com/stock/rhhby#OTC">RHHBY</a>) in the field of respiratory and ophthalmology)</li>
	<li>PLx Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXP#NASDAQ">PLXP</a>)</li>
	<li>PRA Health Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAH#NASDAQ">PRAH</a>)</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAV#NASDAQ">SWAV</a>)</li>
	<li>Syneos Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNH#NASDAQ">SYNH</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows May 25)

<ul>
	<li>89bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>)</li>
	<li>Allogene Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>)</li>
	<li>Amicus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>)</li>
	<li>Atreca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>)</li>
	<li>Axcella Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>)</li>
	<li>Aytu Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>)</li>
	<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>)</li>
	<li>Chembio Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCXI#NASDAQ">CCXI</a>)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>Impel NeuroPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>)</li>
	<li>Intercept Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICPT#NASDAQ">ICPT</a>)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>)</li>
	<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>)</li>
	<li>Nymox Pharmaceutical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMX#NASDAQ">NYMX</a>)</li>
	<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>)</li>
	<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>)</li>
	<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Nabriva&#39;s Antibiotic Aces a Late-stage Trial In China.</h3>

Nabriva Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBRV#NASDAQ">NBRV</a>) and partner Sinovant Sciences announced positive topline results from Sinovant&#39;s Phase 3 bridging study of lefamulin in Chinese adults with community-acquired bacterial pneumonia.

Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response at Test of Cure, compared to 71.4% of patients treated with moxifloxacin.

Consistent with previously reported clinical trial results, lefamulin was observed to be generally safe and well-tolerated, with an overall rate of treatment-emergent adverse events comparable to that of moxifloxacin.

Sinovant also announced an agreement with Sumitomo Pharmaceuticals to acquire development and commercialization rights for lefamulin in Greater China.

<a href="https://www.benzinga.com/general/biotech/19/11/14805019/biotech-stock-on-the-radar-nabriva-and-its-novel-antibiotic-portfolio">Nabriva&#39;s </a> Lefamulin was approved to treat CABP in the U.S. in August&nbsp;2019 and is marketed under the trade name Xenleta.

Nabriva shares jumped 40.54% to $2.08 in after-hours trading.

<h3>Travere Will Not Pursue Accelerated Approval of Drug to Treat Kidney Scarring In Second Half of 2021</h3>

Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) said it received final pre-NDA meeting minutes, wherein the FDA acknowledged the high unmet need for approved therapies for the treatment of focal segmental glomerulosclerosis but indicated the available data from the interim assessment of the DUPLEX study evaluating its sparsentan for the indication would not be adequate to support an accelerated approval at this time.

The company said it now no longer expects to submit for accelerated approval for FSGS in the U.S. during the second half of 2021.

Subject to further discussion with the FDA, the company believes that it may be possible to provide sufficient additional estimated glomerular filtration data from in the first half of 2022. The FDA has encouraged the company to request a follow-up meeting to further explore this option in greater detail, and a Type A meeting is expected to occur in the third quarter of 2021.

The stock slipped 8.45% to $16.25 in after-hours trading.

<h3>Larimar&#39;s Phase 1 Study of Friedreich&#39;s Ataxia Placed On Clinical Hold</h3>

Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) said the FDA has placed its CTI-1601 clinical program on hold and that it will not be closing a previously announced private placement financing. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich&#39;s ataxia, who are unable to produce enough of this essential protein.

The clinical hold follows the previous notification by Larimar to the FDA of mortalities that occurred at the highest dose levels in an ongoing 180-day non-human primate toxicology study. CTI-1601 is currently in Phase 1 clinical trials in the U.S.,

The stock plunged 45.23% to $7.40 in after-hours trading.

<h3>Qiagen, Mirati to Develop Companion Diagnostic For KRAS Mutant Cancers</h3>

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) and Mirati Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTX#NASDAQ">MRTX</a>) announced a global collaboration to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRAS-G12C mutation who may benefit from treatment with adagrasib, Mirati&#39;s investigational oral small molecule inhibitor of KRAS-G12C.

The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer, and allows for further development of tests for other Mirati oncology programs.

<h3>NeoVasc Notified of Non-compliance With Nasdaq Listing Standards</h3>

NeoVasc Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCN#NASDAQ">NVCN</a>) said it has received written notification from the Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq.

The company said it has been provided 180 calendar days, or until November 22, to regain compliance.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/20890405/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates </a>

<h3>Altimmune&#39;s Intranasal COVID-19 Vaccine Found Effective Against South African Variants In Animal Study</h3>

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa.

B.1.351 carries multiple mutations in the receptor-binding domain including the E484K mutation that has been shown to substantially decrease the ability of authorized vaccines to neutralize the virus.

The stock was up 6.61% at $12.68 in premarket trading Wednesday.

<h3>Selecta Gains On Insider Buying</h3>

Selecta Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELB#NASDAQ">SELB</a>) revealed in a filing that Timothy Springer, a director of the board, bought 2,773,479 shares of the company at $3.19 apiece. The stock gained 9.52% to $3.91 in after-hours trading.

<h3>Neuroone Announces Uplisting to Nasdaq</h3>

NeuroOne Medical Technologies Corporation Common Stock (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#OTC">NMTC</a>), a MedTech company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, said its shares have been approved to uplist to the Nasdaq. Trading of the shares on the Nasdaq is expected to begin effective Wednesday, under the Company&#39;s existing ticker symbol &quot;NMTC&quot;.

<h3>On The Radar</h3>

<h3>Clinical Readouts/Presentations</h3>

Chiasma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHMA#NASDAQ">CHMA</a>) is scheduled to virtually present at the American Association of Clinical Endocrinology 2021 Annual meeting encore new data from the MPOWERED Phase 3 study of Mycapssa in adults with acromegaly.

<h3>Earnings</h3>

BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) (before the market open)

Small Cap

Pre-Market Outlook

The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing

Movers

Trading Ideas

NeuroOne Medical Technologies Shares Resume Trade

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock moved upwards by 27.11% to $4.5 during Thursday&#39;s regular session. As of 12:30 EST, this security is trading at a volume of 19.5 million shares, making up 208.68% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $262.3 million.</li>
	<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) stock rose 21.6% to $8.5. As of 12:30 EST, this security is trading at a volume of 4.0 million shares, making up 1551.29% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $361.4 million.</li>
	<li>Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) stock moved upwards by 15.33% to $26.99. Arcus Biosciences&#39;s stock is trading at a volume of 2.5 million shares as of 12:30 EST. This is 457.43% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.9 billion.</li>
	<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares rose 13.73% to $6.66. As of 12:30 EST, NeuroOne Medical Tech&#39;s stock is trading at a volume of 11.8K, which is 92.16% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $79.6 million.</li>
	<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 13.36% to $11.63. Trading volume for this security as of 12:30 EST is 394.3K, which is 17.07% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $279.9 million.</li>
	<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares increased by 12.38% to $24.14. Vaxcyte&#39;s stock is trading at a volume of 155.7K shares as of 12:30 EST. This is 58.33% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock decreased by 25.65% to $25.88 during Thursday&#39;s regular session. Trading volume for this security as of 12:30 EST is 806.4K, which is 4277.27% of its average full-day volume over the last 100 days.</li>
	<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock decreased by 12.23% to $7.97. Trading volume for Aesthetic Medical Intl&#39;s stock is 571.6K as of 12:30 EST. This is 148.93% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $188.0 million. The company&#39;s, Q1 earnings came out today.</li>
	<li>4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) stock declined by 12.15% to $21.77. The current volume of 425.9K shares is 348.06% of 4D Molecular Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $582.2 million.</li>
	<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 10.55% to $2.63. As of 12:30 EST, Adial Pharmaceuticals&#39;s stock is trading at a volume of 1.3 million, which is 185.17% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $47.8 million.</li>
	<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares declined by 9.55% to $1.8. Trading volume for this security as of 12:30 EST is 11.0 million, which is 373.25% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $225.0 million.</li>
	<li>Idera Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDRA#NASDAQ">IDRA</a>) stock fell 7.98% to $1.27. As of 12:30 EST, this security is trading at a volume of 3.5 million shares, making up 102.24% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $63.5 million.</li>
</ul>

&nbsp;

&nbsp;

Intraday Update

12 Health Care Stocks Moving In Thursday's Intraday Session

ADIL

ALLO

ATNF

AXLA

AYTU

BCEL

BLRX

BOLT

CCXI

CEMI

CHMA

CHRS

CRBP

EPIX

ETNB

FDMT

FOLD

ICPT

IDRA

IMPL

IONS

KLDO

KNSA

LRMR

LYRA

MRTX

NBRV

NMTC

NVCN

NYMX

PCVX

PIRS

PLXP

PRAH

PRTG

QGEN

RCUS

RHHBY

SELB

SPRB

SWAV

SYNH

TVTX

VKTX

VVOS

Less invasive, more cost-effective solution may enhance neurosurgery for people with neurological brain conditions, including epilepsy

<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.n1mtc.com%2F&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=NeuroOne+Medical+Technologies+Corporation&amp;index=1&amp;md5=e65ee15e798634bafefb2d2a6e7b775f" shape="rect">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from brain and spine-related neurological disorders, today announces the release of its white paper, "<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.n1mtc.com%2Fin-the-news&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=Thin-Film+Electrodes+Show+Potential+for+Transforming+Neurosurgery&amp;index=2&amp;md5=51fb91fef570d4dab203fe61947e8370" shape="rect">Thin-Film Electrodes Show Potential for Transforming Neurosurgery</a>," exploring recent advances in thin-film technology that may offer a less invasive, more cost-effective solution to enhance neurosurgery for people with brain conditions, including epilepsy, Parkinson's disease, dystonia, essential tremors and pain management for failed back surgery syndrome. Including commentary from Kip Ludwig, Ph.D., Associate Professor of Biomedical Engineering Adjunct Faculty of Neurological Surgery, University of Wisconsin, the white paper points to the flexible thin-film substrate as having many benefits compared to existing technology that is currently used clinically.

"Fundamentally, this innovative, patented thin-film technology offers advantages over currently commercially available electrodes, including more efficient automated manufacturing processes," says Dave Rosa, president and CEO, NeuroOne. "EVO Cortical Electrodes (EVO), the first FDA-cleared thin-film electrodes for recording, monitoring and stimulating brain tissue for up to 30 days, have demonstrated a reduction in the brain's <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F2421149l&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=immunological+response&amp;index=3&amp;md5=2032aca1aa15656190d9295149a7c70e" shape="rect">immunological response</a>, potentially improving patient <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F348308&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=comfort&amp;index=4&amp;md5=6c37557fd2195c34495a58c3356e018f" shape="rect">comfort</a> and <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F349745&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=reducing&amp;index=5&amp;md5=8dbbf0ac0c1e68c42ec99804c582a529" shape="rect">reducing</a> signal artifacts."

EVO may also reduce time for diagnosis to provide much-needed cost savings for hospitals and patients. In initial pre-clinical clinical testing, EVO demonstrated the ability to provide higher fidelity recordings, which may allow physicians to more precisely identify the brain tissue responsible for causing seizures. Because of its potential for minimally invasive placement, along with its single tail design, EVO may mean fewer post-procedure complications and may potentially <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F348308&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=reduce&amp;index=6&amp;md5=ae38f9e00e257371eab716a9f2bb476d" shape="rect">reduce</a> the risk of infection.

"I'm looking forward to seeing the NeuroOne thin-film electrode technology become widely available clinically," says Dr. Ludwig. "The NeuroOne manufacturing process should be extensible to diverse areas in neuromodulation such as deep brain stimulation and spinal cord stimulation. One can imagine this platform technology soon being used to create patient specific electrode configurations to treat a host of diseases/disorders."

Rosa adds, "Building and improving upon old and innovative technologies that have been in use for decades, this significant medical technology is poised to hit the market."

About NeuroOne
 NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, pain management for failed back surgery syndrome and other related neurological disorders that may improve patient outcomes and reduce procedural costs. Visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.n1mtc.com%2F&amp;esheet=52297639&amp;newsitemid=20200930005250&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.n1mtc.com%2F&amp;index=7&amp;md5=7a27db0a9fd57131de08aa85b609d1e0" shape="rect">https://www.n1mtc.com/</a>.

Forward Looking Statements
 This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the timing of the Company&#39;s regulatory submissions, potential regulatory approval, commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties inherent in the development process of our technology, delays in the manufacturing process, changes in regulatory requirements or decisions of regulatory authorities, , the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

&#34;Caution: Federal law restricts this device to sale by or on the order of a physician.&#34;
<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20200930005250r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20200930005250/en/" rel="nofollow">https://www.businesswire.com/news/home/20200930005250/en/</a>

Press Releases

NeuroOne Medical Technologies Corporation Releases White Paper: Thin-Film Electrodes Show Potential for Transforming Neurosurgery

<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.n1mtc.com%2F&amp;esheet=52296417&amp;newsitemid=20201006005065&amp;lan=en-US&amp;anchor=NeuroOne+Medical+Technologies+Corporation&amp;index=1&amp;md5=3b5810f790b0333113981202b5517fb1" shape="rect">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today provides an update on its commercialization plans.

Dave Rosa, president and CEO, NeuroOne, says, "We are pleased to announce that we have received finished product from all of our vendors for the initial launch of the EVO Cortical Electrode (EVO) product line and will soon begin the final stages of assembling, packaging, labeling and sterilizing the product for our initial product launch. In cooperation with our distribution partner, Zimmer Biomet, the initial launch sites have been confirmed and we are optimistic the Company will have available product for sale in November. In addition, the Company will collect feedback from the launch sites with the intent of presenting at future trade shows and potentially publishing these results."

Rosa continues, "Applications for these electrodes are expected for recording brain activity in epilepsy patients as well as brain mapping in patients with brain tumors that require resection. Many companies have been working on commercializing hi-density electrodes for years and we are extremely proud to be the first to receive FDA clearance. As we establish the technology in the commercial marketplace, the Company remains committed to pursuing the development of additional products that offer therapeutic properties in addition to recording capabilities in order to take full advantage of the technology. To support those efforts, we are currently expanding our development team in an order to expedite development."

EVO Cortical Electrodes, intended for recording, monitoring and stimulating brain tissue for up to 30 days, may have the potential to change the landscape of neurosurgical procedures. The technology, utilizes sophisticated, automated manufacturing processes and offers several advantages including a thin-film lightweight design, high resolution capabilities, reduced <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F2421149&amp;esheet=52296417&amp;newsitemid=20201006005065&amp;lan=en-US&amp;anchor=immunological+response&amp;index=2&amp;md5=cf09dbac5c57ceebcb6e64efb03cf427" shape="rect">immunological response</a>—as demonstrated in pre-clinical studies—and the potential to be placed in a minimally invasive manner.

About NeuroOne
 NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.n1mtc.com&amp;esheet=52296417&amp;newsitemid=20201006005065&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.n1mtc.com&amp;index=3&amp;md5=032c51948401b1feb79009963f022235" shape="rect">https://www.n1mtc.com</a>.

Forward Looking Statements
 This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the timing and extent of product launch and commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;
<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20201006005065r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20201006005065/en/" rel="nofollow">https://www.businesswire.com/news/home/20201006005065/en/</a>

NeuroOne Medical Technologies Corporation Provides Commercialization Update for EVO Cortical Electrode

EDEN PRAIRIE, Minn., Dec. 3, 2020 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3001261-1&amp;h=1449217655&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota.

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="NeuroOne Medical Technologies Incorporated (OTC:<a class="ticker" href="/stock/NMTC#OTC">NMTC</a>) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. We are currently focused on the development and commercialization of patented thin-film electrode technology for electrocorticography (ECoG) and stereoelectroencephalography (sEEG) recording of brain activity." alt="NeuroOne Medical Technologies Incorporated (OTC:<a class="ticker" href="/stock/NMTC#OTC">NMTC</a>) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. We are currently focused on the development and commercialization of patented thin-film electrode technology for electrocorticography (ECoG) and stereoelectroencephalography (sEEG) recording of brain activity."></img>
 </a>
 

 </div>
The procedure was performed by Jamie Van Gompel, M.D., from November 23rd through November 27th on a patient that had drug resistant epilepsy and utilized the NeuroOne Evo electrode technology to perform recording, functional mapping and stimulation of the brain. Three NeuroOne electrodes were also used in addition to four Ad-Tech Medical electrodes during the procedure. In addition to recording a seizure, the NeuroOne electrodes also recorded evidence of pre-seizure activity which may be critical in developing treatments to prevent the onset of seizures.
Dr. Van Gompel stated, &#34;Thin film electrode technology has been in development for years and in addition to its thin film, light weight properties, the electrodes also conformed very securely to the brain. The recordings were sharp and clearly noted evidence of pre-seizure activity. We were also able to visualize the brain under CT imaging which was very useful. We are very excited to continue to explore the potential clinical advantages of this technology for our patients,&#34; said Dr. Van Gompel, one of the co-developers of this technology.
Dave Rosa, president and CEO, NeuroOne, says, &#34;After years of development it was exciting to witness the initial validation of our Evo cortical electrode technology at Mayo Clinic. We are grateful to all the institutions that helped provide valuable guidance along the way and look forward to making our technology available to a multitude of centers through our distribution and development partner Zimmer Biomet. We hope to add to this line next year with a family of sEEG electrodes that offer a similar feature set as the Evo cortical product portfolio.&#34; 
Evo Cortical Electrodes, intended for recording, monitoring and stimulating brain tissue for up to 30 days, may have the potential to change the landscape of neurosurgical procedures offering potential benefit to both physicians and patients. The technology utilizes  sophisticated automated manufacturing processes and offers several advantages including a thin-film lightweight design, high resolution capabilities, reduced <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3001261-1&amp;h=610164894&amp;u=https%3A%2F%2Fwww.aesnet.org%2Fmeetings_events%2Fannual_meeting_abstracts%2Fview%2F2421149&amp;a=immunological+response" rel="nofollow">immunological response</a>—as demonstrated in a pre-clinical study—and the potential to be placed in a minimally invasive manner. 
NeuroOne received FDA clearance for its Evo cortical technology in November 2019. It plans to submit a second 510(k) application for its sEEG electrode technology in the first half of 2021 to bolster its product portfolio for use in recording, monitoring and stimulating brain tissue for up to 30 days. In addition, the Company continues developing therapeutic electrodes for use in Parkinson&#39;s Disease, epilepsy and back pain due to failed back surgery.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
In July 2020, NeuroOne executed a distribution and development agreement with Zimmer Biomet that provides exclusive rights to distribute NeuroOne&#39;s current Evo cortical electrodes and its sEEG electrode product line once it has received FDA clearance.
Mayo Clinic and Dr. Van Gompel have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not for profit mission in patient care, education and research.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3001261-1&amp;h=1668523637&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>. 
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing and extent of product launch and commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL11817&amp;sd=2020-12-03"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-first-human-commercial-use-of-its-evo-cortical-electrode-at-mayo-clinic-301185612.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-first-human-commercial-use-of-its-evo-cortical-electrode-at-mayo-clinic-301185612.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne® Medical Technologies Corporation Announces First Human Commercial Use of its Evo™ Cortical Electrode at Mayo Clinic

EDEN PRAIRIE, Minn., Jan. 7, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3028327-1&amp;h=1720985631&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Ronald McClurg, an experienced senior financial industry executive, as Chief Financial Officer of NeuroOne Medical Technologies Corporation. Mr. McClurg has over 30 years of financial leadership experience with both public and privately held companies. He has held the role of CFO for a number of public companies including Orthomet, Inc., Video Sentry Corporation, and Insignia Systems, Inc. He also held the role of CFO at Incisive Surgical, a privately held medical device company. He began his career in public accounting with Ernst and Young, where he earned his CPA certificate. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1396017/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1396017/NeuroOne_Logo.jpg" title="" alt=""></img>
 </a>
 

 </div>
Dave Rosa, President and CEO of NeuroOne, says, &#34;Over the past quarter the Company has made great progress in achieving key milestones and building our infrastructure. With our future goal to uplist to a major national securities exchange, it became critical to add a seasoned senior financial executive such as Ron. His broad experience with both public and private companies as well as his familiarity with medical device companies make him an ideal fit for the role of CFO at NeuroOne. We are very fortunate to have him as part of the NeuroOne family and look forward to working with him.&#34;
Mr. McClurg states, &#34;I&#39;m excited to join the NeuroOne team because I believe in the Company&#39;s growth strategy to improve outcomes for patients suffering from neurological disorders and enhance shareholder value. I feel that my skills and experience will complement those of the rest of the NeuroOne leadership team.&#34;
NeuroOne received FDA clearance for its Evo&#x2122; cortical electrode technology in November 2019. It plans to submit a second 510(k) application for its sEEG electrode technology in the first half of 2021 to bolster its product portfolio for use in recording, monitoring and stimulating brain tissue for up to 30 days. In addition, the Company continues developing therapeutic electrodes for use in Parkinson&#39;s Disease, epilepsy and back pain due to failed back surgery.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
In July 2020, NeuroOne executed a distribution and development agreement with Zimmer Biomet that provides exclusive rights to distribute NeuroOne&#39;s current Evo cortical electrodes and its sEEG electrode product line once it has received FDA clearance.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3028327-1&amp;h=1401339933&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>. 
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing and extent of product launch and commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the Company may not be able to successfully uplist to a national securities exchange; risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL39625&amp;sd=2021-01-07"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-appoints-ronald-mcclurg-experienced-financial-industry-executive-as-chief-financial-officer-301202440.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-appoints-ronald-mcclurg-experienced-financial-industry-executive-as-chief-financial-officer-301202440.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer

EDEN PRAIRIE, Minn., Jan. 12, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has entered into a definitive purchase agreement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock to certain investors in a private placement.  Each share of common stock and corresponding warrant is being sold at an aggregate purchase price of $1.00 for anticipated gross proceeds of $12,500,000. The proposed offering is anticipated to close on or about January 14, 2021, subject to the satisfaction of customary closing conditions. Proceeds from the proposed offering are expected to be used for general corporate and working capital purposes. Kestrel Merchant Partners LLC is acting as the exclusive sponsor and The Benchmark Company, LLC is acting as the sole placement agent for the proposed offering. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. 
The securities to be sold in the proposed offering have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;) or an applicable exemption from such registration requirements. NeuroOne has agreed to file a registration statement with the SEC registering the resale of the shares of its common stock and the warrants sold in the proposed offering, as well as the shares of its common stock issuable upon exercise of such warrants. 
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward-looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the information expressed or implied by these forward-looking statements. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, including any forward looking statements regarding the proposed offering, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to the closing date of the proposed offering, the use of proceeds of the proposed offering, and the risks described under the heading &#34;Risk Factors&#34; in our filings with the SEC. These forward-looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL46524&amp;sd=2021-01-12"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-private-placement-301206907.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-private-placement-301206907.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation Announces Private Placement

EDEN PRAIRIE, Minn., Jan. 15, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3038490-1&amp;h=4206183458&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the closing of a previously announced private placement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock. Each share of common stock and corresponding warrant is being sold at an aggregate purchase price of $1.00 for gross proceeds of $12,500,000. The exercise price of each warrant is $1.75 per share and are exercisable for a period of five years from the date of issuance. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
After deducting the placement agent&#39;s fees and other offering expenses to be paid by the Company, the Company received net proceeds of approximately $11,500,000. The Company expects to use the net proceeds to pursue a proposed Nasdaq uplisting, accelerate research and development efforts, potentially advance a second commercial product launch in 2021, pending regulatory clearance, and other general corporate purposes.
Kestrel Merchant Partners LLC acted as the exclusive sponsor and The Benchmark Company, LLC acted as the sole placement agent in connection with the offering. 
Dave Rosa, President and CEO, NeuroOne, says, &#34;The completion of this financing led by sophisticated institutional investors with substantial experience investing in medical device technologies represents another major milestone and validation for the Company. We expect that this capital positions the Company well for a potential uplisting to the Nasdaq Stock Market without requiring an additional capital raise while also providing runway into 2022. As previously communicated, this remains a priority for the Company in 2021.&#34;
&#34;We also expect that this financing will allow us to complete a submission to the FDA for our Evo sEEG electrode, which would also be distributed by our commercialization partner Zimmer Biomet if they exercise their exclusive distribution rights. We believe we are well-positioned to accelerate development of the therapeutic technologies we have targeted that broaden the application and commercial opportunity for the Company.&#34;
NeuroOne received FDA clearance for its Evo cortical technology in November 2019. It plans to submit a second 510(k) application for its sEEG electrode technology in the first half of 2021 to bolster its product portfolio for use in recording, monitoring and stimulating brain tissue for up to 30 days. In addition, the Company continues developing therapeutic electrodes for use in Parkinson&#39;s Disease, epilepsy and back pain due to failed back surgery.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
In July 2020, NeuroOne executed a distribution and development agreement with Zimmer Biomet that provides exclusive rights to distribute NeuroOne&#39;s current Evo cortical electrodes and its sEEG electrode product line once it has received FDA clearance.
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Act&#34;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock and the warrants issued in this private placement as well as the shares of common stock issuable upon exercise of such warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3038490-1&amp;h=3483872288&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>. 
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential uplisting on the Nasdaq Stock Market, the timing and extent of product launch and commercialization of the technology (including the targeted product launch in 2021), the use of proceeds from the private placement, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL50029&amp;sd=2021-01-15"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-closes-12-5-million-private-placement-with-certain-prominent-institutional-investors-advances-towards-nasdaq-uplisting-301209124.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-closes-12-5-million-private-placement-with-certain-prominent-institutional-investors-advances-towards-nasdaq-uplisting-301209124.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting

EDEN PRAIRIE, Minn., Feb. 23, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3075301-1&amp;h=3865555475&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that it has successfully met the first performance milestone in the distribution and development agreement that was signed with Zimmer Biomet on July 20, 2020. In addition to acquiring the exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
Dave Rosa, President and CEO, NeuroOne, says, &#34;The Company is quite pleased to meet this development milestone. Coupled with the announcement of our recent financing, we are confident that our partnership with Zimmer Biomet and the progress in our sEEG program position the Company well to offer a unique full complement of brain recording diagnostic technology in 2021 and beyond.&#34;
NeuroOne announced on January 15, 2021, the closing of a $12.5 Million Private Placement with certain institutional investors with the intent to use the proceeds for a proposed Nasdaq uplisting, acceleration of research and development efforts, a potential second commercial product launch in 2021 pending regulatory clearance, and other general corporate purposes.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019. 
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3075301-1&amp;h=3547683345&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential uplisting on the Nasdaq Stock Market, the timing of submission of our second 510(k) application, the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology (including the targeted product launch in 2021), the use of proceeds from the private placement, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL87518&amp;sd=2021-02-23"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-successful-completion-of-first-performance-milestone-in-zimmer-biomet-agreement-301233035.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-successful-completion-of-first-performance-milestone-in-zimmer-biomet-agreement-301233035.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement

Detroit, Michigan--(Newsfile Corp. - March 18, 2021) - NeuroOne Medical Technologies Corporation (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>) will be presenting at the Benzinga Biotech Small Cap Conference taking place on March 24-25, 2021. We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, deal-making and discovery.About the Benzinga Biotech Small Cap ConferenceThe Benzinga Biotech Small Cap Conference bridges the gap between biotech companies, investors, and traders. Discover the companies in the biotech space who are helping to bring the world back to normalcy in the wake of the COVID-19 pandemic.For more information on the conference please visit: <a href="https://www.newsfilecorp.com/redirect/Q82Bh8xYB">https://www.benzinga.com/events/small-cap/biotech/</a>.We look forward to seeing you there.For further information:NeuroOne Medical Technologies Corporation Dave Rosa <a href="mailto:daver@n1mtc.com">daver@n1mtc.com</a> <a href="https://www.newsfilecorp.com/redirect/mpjzhR2X0">www.n1mtc.com</a><img src="https://orders.newsfilecorp.com/files/6570/77609_1c98f5ca74110ad7_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" />To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/kwXrh5eDY">https://www.newsfilecorp.com/release/77609</a><img src="https://www.newsfilecorp.com/newsinfo/77609/197" alt="" />

NeuroOne Medical Technologies Corporation Presenting at the Benzinga Biotech Small Cap Conference

EDEN PRAIRIE, Minn., March 30, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3112874-1&amp;h=3980306398&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that CEO Dave Rosa will make a live appearance on the Big Biz Show, April 5, 2021, 1:15 CST. Rosa will discuss how electrical stimulation is changing treatment modalities today, what the future may hold for this therapy and NeuroOne&#39;s potential role. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
The Big Biz Show, a syndicated television program that has been running for over 20 years, combines business, personal finance and investing topics with lighthearted comedy. Hosted by Emmy-award winning Bob Sullivan and his partner comedian Russ Stolnack, the show can be watched on the following media outlets:
<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">Weekdays YouTOO America Television Network </li><li xmlns="http://www.w3.org/1999/xhtml">Weekdays Biz TV Television Network </li><li xmlns="http://www.w3.org/1999/xhtml">Weekdays iHeart Radio </li><li xmlns="http://www.w3.org/1999/xhtml">Weekdays The Armed Forces Radio Network (Bases and Ships Worldwide) </li><li xmlns="http://www.w3.org/1999/xhtml">Weekdays Biz Talk Radio Network </li><li xmlns="http://www.w3.org/1999/xhtml">Podcasts available on iHeart Radio, Apple, TuneIn, and many more.</li></ul>Check local listings or follow NeuroOne on social media to stay up to date on this broadcast.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3112874-1&amp;h=3626782684&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame. 
NeuroOne received FDA clearance for its Evo cortical technology in November 2019. 
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential uplisting on the Nasdaq Stock Market, the timing of submission of our second 510(k) application, the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology (including the targeted product launch in 2021), what the future may hold for electrical stimulation and NeuroOne&#39;s potential role, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL25956&amp;sd=2021-03-30"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-featured-appearance-on-nationally-syndicated-television-the-big-biz-show-301258511.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-featured-appearance-on-nationally-syndicated-television-the-big-biz-show-301258511.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation Announces Featured Appearance on Nationally Syndicated Television: The Big Biz Show

EDEN PRAIRIE, Minn., March 31 , 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3114314-1&amp;h=487126571&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=NeuroOne+Medical+Technologies+Corporation" rel="nofollow">NeuroOne Medical Technologies Corporation</a> (OTCQB:<a class="ticker" href="/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-3, effective at 4:01 pm Eastern time today. Beginning tomorrow, April 1, 2021, NeuroOne&#39;s common stock will trade on a split-adjusted basis.

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, &#34;As part of our corporate strategy to uplist to a major exchange, we are excited to take the next step in this process. In addition to our existing shareholder base, we are grateful to our new institutional investors that have provided important growth capital to launch new products and uplist the company. We look forward to updating the market on our future progress as we move forward with a major national exchange.&#34;
Upon effectiveness, the reverse split will cause every 3 shares of NeuroOne&#39;s issued and outstanding common stock to be automatically combined and converted into 1 issued and outstanding share of common stock, par value $0.001 per share. The reverse stock split will reduce the number of shares of common stock issuable upon the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the exercise prices of such stock options and warrants.
NeuroOne&#39;s common stock will continue to trade on the OTCQB under the symbol &#34;NMTC.&#34; The new CUSIP number for the common stock following the reverse split is 64130M 209.
About NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3114314-1&amp;h=672800297&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame. 
NeuroOne received FDA clearance for its Evo cortical technology in November 2019. 
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential uplisting on the Nasdaq Stock Market, the timing of submission of our second 510(k) application, the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology (including the targeted product launch in 2021), what the future may hold for electrical stimulation and NeuroOne&#39;s potential role, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;
 

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL27413&amp;sd=2021-03-31"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-reverse-stock-split-as-part-of-uplisting-strategy-to-major-exchange-301259172.html">http://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-reverse-stock-split-as-part-of-uplisting-strategy-to-major-exchange-301259172.html</a>
SOURCE NeuroOne Medical Technologies Corporation

Stock Split

NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange

EDEN PRAIRIE, Minn., April 27, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3141631-1&amp;h=3503675281&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D487126571%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3DNeuroOne%2BMedical%2BTechnologies%2BCorporation&amp;a=NeuroOne+Medical+Technologies+Corporation%C2%A0" rel="nofollow">NeuroOne Medical Technologies Corporation </a>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Hijaz Haris, as its Vice President of Marketing. Mr. Haris joins NeuroOne from Medtronic plc, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) where he was Senior Global Marketing Director for Brain Modulation.
Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, &#34;Hijaz&#39;s appointment strengthens our executive leadership team and addresses a critical gap we had entering 2021. We believe his broad experience in the neurology space will help us maximize the value of our current product portfolio, as well as identify new areas for product development to accelerate our growth.&#34;
Hijaz Haris, VP of Marketing, commented, &#34;I&#39;m thrilled to join such a talented and innovative team, as the applications and market opportunities for NeuroOne&#39;s cutting edge electrode technology are tremendous.  Furthermore, I&#39;m inspired by the Company&#39;s mission &#39;to be the global leader in cEEG and sEEG recording, stimulation and ablation, owning the procedures from diagnosis through treatment. I look forward to drawing on two decades of relevant medical device expertise to help NeuroOne meet and exceed these trailblazing goals.&#34; 
Hijaz Haris joins NeuroOne with more than 20 years of experience at Medtronic.  Most recently he led Global Marketing for Medtronic&#39;s Brain Modulation business, where he helped refresh the Deep Brain Stimulation product pipeline and led the business through a period of new competitive entries, new product launches, and various distribution partnerships.  Prior to that Mr. Haris held various roles of increasing responsibility across multiple business segments (Cardiac Rhythm Management, Neuroscience, Neuromodulation) and business functions (Product and Strategic Marketing, Corporate Sales, Sales Strategy, and Corporate Finance).  In his career with Medtronic he was part of new category launches and led significant commercial initiatives across multiple segments.
About NeuroOne  NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3141631-1&amp;h=2310683252&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D672800297%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3Dhttps%253A%252F%252Fwww.n1mtc.com&amp;a=https%3A%2F%2Fwww.n1mtc.com%C2%A0" rel="nofollow">https://www.n1mtc.com </a>.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology, what the future may hold for electrical stimulation and NeuroOne&#39;s potential role, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;
  
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL55447&amp;sd=2021-04-27"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-appoints-medtronic-veteran-hijaz-haris-as-vice-president-of-marketing-301277294.html">http://www.prnewswire.com/news-releases/neuroone-appoints-medtronic-veteran-hijaz-haris-as-vice-president-of-marketing-301277294.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Appoints Medtronic Veteran, Hijaz Haris, as Vice President of Marketing

EDEN PRAIRIE, Minn., May 19, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3167590-1&amp;h=383940313&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D487126571%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3DNeuroOne%2BMedical%2BTechnologies%2BCorporation&amp;a=NeuroOne+Medical+Technologies+Corporation%C2%A0" rel="nofollow">NeuroOne Medical Technologies Corporation </a>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will participate in the upcoming investor conference:

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
Oppenheimer Medtech, Tools and Diagnostics Summit 
<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">May 26, 2021 (On demand presentation for registered participants and available for 1x1 meetings) <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3167590-1&amp;h=2989778366&amp;u=https%3A%2F%2Fwww.oppenheimer.com%2Fevents%2F2021%2Fmedtech-day-conference.aspx&amp;a=https%3A%2F%2Fwww.oppenheimer.com%2Fevents%2F2021%2Fmedtech-day-conference.aspx" rel="nofollow">https://www.oppenheimer.com/events/2021/medtech-day-conference.aspx</a>  </li></ul>To schedule a one-on-one meeting with management, please contact your conference representative or <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3167590-1&amp;h=2889727741&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DmAG8CWgG0xq8wmuKKd-mhFYlfTxnljctqNP58p4a00kd28j6vwJn84iMuRsiaFh6n-b_6zVOzj4-SobFupRyBOQiz6qXWjmcQA9_5A0mhxM%3D&amp;a=James%40HaydenIR.com" rel="nofollow">James@HaydenIR.com</a>.
About NeuroOne  NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3167590-1&amp;h=1334680380&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D672800297%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3Dhttps%253A%252F%252Fwww.n1mtc.com&amp;a=https%3A%2F%2Fwww.n1mtc.com%C2%A0" rel="nofollow">https://www.n1mtc.com </a>.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL81822&amp;sd=2021-05-19"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-to-participate-at-the-oppenheimer-medtech-tools-and-diagnostics-summit-on-may-26th-2021-301294364.html">http://www.prnewswire.com/news-releases/neuroone-to-participate-at-the-oppenheimer-medtech-tools-and-diagnostics-summit-on-may-26th-2021-301294364.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne to Participate at the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26th, 2021

EDEN PRAIRIE, Minn., May 25, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3173067-1&amp;h=4030012363&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D487126571%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3DNeuroOne%2BMedical%2BTechnologies%2BCorporation&amp;a=NeuroOne+Medical+Technologies+Corporation%C2%A0" rel="nofollow">NeuroOne Medical Technologies Corporation </a>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#OTCQB">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it has been approved to uplist to The Nasdaq Capital Market. Trading on The Nasdaq Capital Market is expected to begin effective tomorrow morning at the open of market, May 26th, 2021 under the Company&#39;s existing ticker symbol &#34;NMTC&#34;. The Company&#39;s common stock will continue to trade on the OTC Markets quotation system on the OTCQB until trading commences on The Nasdaq Capital Market.

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
NeuroOne CEO Dave Rosa says, &#34;The team at NeuroOne has worked relentlessly for the past four years to position the Company to accomplish this major milestone. Nasdaq has an established reputation for being an exchange associated with emerging growth stocks and we believe our uplisting will elevate the Company&#39;s corporate profile with current and prospective investors, and the financial community as a whole.  As the Company continues to grow, we are hopeful our Nasdaq uplisting will generate even greater interest in our Company from leading institutional investment firms across the broader national and international investment community. I want to also thank all of our current and past investors who were critical in helping us accomplish this critical milestone.&#34;
About NeuroOne  NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3173067-1&amp;h=1067287387&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>. 
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing of trading on the Nasdaq Stock Market, the elevation of the Company&#39;s profile with investors, the increase in interest in the Company from leading institutional investment firms across the broader national and international investment community, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL87390&amp;sd=2021-05-25"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-announces-approval-for-nasdaq-capital-market-listing-trading-expected-to-commence-tomorrow-may-26th-2021-under-the-symbol-nmtc-301298290.html">http://www.prnewswire.com/news-releases/neuroone-announces-approval-for-nasdaq-capital-market-listing-trading-expected-to-commence-tomorrow-may-26th-2021-under-the-symbol-nmtc-301298290.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Announces Approval for Nasdaq Capital Market Listing; Trading Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC

EDEN PRAIRIE, Minn., June 2, 2021 /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3179905-1&amp;h=315021209&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D487126571%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3DNeuroOne%2BMedical%2BTechnologies%2BCorporation&amp;a=NeuroOne+Medical+Technologies+Corporation%C2%A0" rel="nofollow">NeuroOne Medical Technologies Corporation </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the formation of a six member advisory board of leading neurosurgeons to assist in the completion of development of a radio frequency ablation electrode intended to record and ablate brain tissue linked to causing seizure activity.

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
The six members that have been appointed to the advisory board are as follows:
<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">Dr. Daniel Couture, Wake Forest Baptist Health </li><li xmlns="http://www.w3.org/1999/xhtml">Dr. Gerald Grant, Stanford University Medical Center </li><li xmlns="http://www.w3.org/1999/xhtml">Dr. Bob Gross, Emory University </li><li xmlns="http://www.w3.org/1999/xhtml">Dr. Zachary Levine, Holy Cross Health, George Washington University </li><li xmlns="http://www.w3.org/1999/xhtml">Dr. Guy McKhann, New York Presbyterian Hospital, Columbia University </li><li xmlns="http://www.w3.org/1999/xhtml">Dr. Jamie Van Gompel, Mayo Clinic</li></ul>NeuroOne CEO Dave Rosa says, &#34;We are honored to have an opportunity to partner with such distinguished neurosurgeons who I believe will be extremely helpful in accelerating our ablation electrode technology program. Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure. The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology.&#34;
About NeuroOne  NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3179905-1&amp;h=1269381756&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3114314-1%26h%3D672800297%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3Dhttps%253A%252F%252Fwww.n1mtc.com&amp;a=https%3A%2F%2Fwww.n1mtc.com%C2%A0" rel="nofollow">https://www.n1mtc.com </a>.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.
Forward Looking Statements  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne&#39;s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;objective,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;target,&#34; &#34;seek,&#34; &#34;contemplate,&#34; &#34;continue&#34; and &#34;ongoing,&#34; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the development of the Company&#39;s ablation electrode technology program, the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology, what the future may hold for electrical stimulation and NeuroOne&#39;s potential role, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &#34;Risk Factors&#34; in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
&#34;Caution: Federal law restricts this device to sale by or on the order of a physician&#34;

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL94292&amp;sd=2021-06-02"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="http://www.prnewswire.com/news-releases/neuroone-introduces-advisory-board-for-ablation-electrode-technology-that-records-and-ablates-brain-tissue-linked-to-seizure-activity-301302094.html">http://www.prnewswire.com/news-releases/neuroone-introduces-advisory-board-for-ablation-electrode-technology-that-records-and-ablates-brain-tissue-linked-to-seizure-activity-301302094.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity

EDEN PRAIRIE, Minn., July 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the company will present at Access to Giving Virtual Conference. 

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
Registration Details Date: Thursday, July 15, 2021 Time: 2 p.m. ET Link: <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3219338-1&amp;h=2469701013&amp;u=https%3A%2F%2Faccess-to-giving.events.issuerdirect.com%2Fsignup&amp;a=https%3A%2F%2Faccess-to-giving.events.issuerdirect.com%2Fsignup" rel="nofollow">https://access-to-giving.events.issuerdirect.com/signup</a> 
To learn more about the event or to schedule a one-on-one meeting with NeuroOne&#39;s management, please visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3219338-1&amp;h=1117030185&amp;u=https%3A%2F%2Fwww.accesstogiving.com%2F&amp;a=https%3A%2F%2Fwww.accesstogiving.com%2F" rel="nofollow">https://www.accesstogiving.com/</a> or email <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="mailto:james@haydenir.com" rel="nofollow">james@haydenir.com</a>. 
About Access to Giving Virtual Conference
Access to Giving is a first-of-its-kind virtual investor conference where companies from microcap all the way up to megacap will have the opportunity to present their story and conduct 1x1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3219338-1&amp;h=1342822104&amp;u=https%3A%2F%2Fwww.n1mtc.com%2F&amp;a=https%3A%2F%2Fwww.n1mtc.com" rel="nofollow">https://www.n1mtc.com</a>.
The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures. 

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL34387&amp;sd=2021-07-07"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/neuroone-to-present-at-access-to-giving-virtual-conference-on-july-15-2021-at-2-pm-et-301326578.html">https://www.prnewswire.com/news-releases/neuroone-to-present-at-access-to-giving-virtual-conference-on-july-15-2021-at-2-pm-et-301326578.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne to Present at Access to Giving Virtual Conference on July 15, 2021 at 2 p.m. ET

EDEN PRAIRIE, Minn., July 28, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the Company will participate in Alliance Global Partners (A.G.P.) Virtual MedTech Summer Conference on July 29, 2021.

 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg" title="(PRNewsfoto/NeuroOne Medical Technologies Corporation)" alt="(PRNewsfoto/NeuroOne Medical Technologies Corporation)"></img>
 </a>
 

 </div>
The event will consist of one-on-one virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with management should contact their A.G.P. representative or <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="mailto:James@HaydenIR.com" rel="nofollow">James@HaydenIR.com</a> .
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#39;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3241529-1&amp;h=1513793665&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3219338-1%26h%3D1342822104%26u%3Dhttps%253A%252F%252Fwww.n1mtc.com%252F%26a%3Dhttps%253A%252F%252Fwww.n1mtc.com&amp;a=https%3A%2F%2Fwww.n1mtc.com.%C2%A0" rel="nofollow">https://www.n1mtc.com. </a>
The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&#39;s Evo&#x2122; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&#39;s disease, epilepsy and pain management due to failed back surgery procedures.

<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
</div>
<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://c212.net/c/img/favicon.png?sn=CL56856&amp;sd=2021-07-28"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/neuroone-to-participate-in-alliance-global-partners-agp-virtual-medtech-summer-conference-on-july-29-2021-301342767.html">https://www.prnewswire.com/news-releases/neuroone-to-participate-in-alliance-global-partners-agp-virtual-medtech-summer-conference-on-july-29-2021-301342767.html</a>
SOURCE NeuroOne Medical Technologies Corporation

NeuroOne to Participate in Alliance Global Partners (A.G.P.) Virtual MedTech Summer Conference on July 29, 2021

Aethlon Medical

Avinger

Biolase

Bellerophon Therapeutics, Inc. - Common Stock

Bellerophon Therapeutics

Biomerica

Check-Cap

Delcath Systems

electroCore

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Hancock Jaffe Laboratories, Inc. - Common Stock

Hancock Jaffe

INVO Bioscience

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

LENSAR

Microbot Medical

Medigus Ltd. - American Depositary Shares

Medigus

Motus GI Hldgs

NanoVibronix

ENDRA Life Sciences

NeuroMetrix

SINTX Technologies

Sensus Healthcare

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Trinity Biotech plc - American Depositary Shares each representing 4 A Ordinary Shares

Recent Quotes

Related Companies

NeuroOne Medical Tech Frequently Asked Questions

How do I buy NeuroOne Medical Tech (NMTC) stock?

Who are NeuroOne Medical Tech's (NMTC) competitors?

What is the target price for NeuroOne Medical Tech (NMTC) stock?

Current Stock Price for NeuroOne Medical Tech (NMTC)?

Does NeuroOne Medical Tech (NMTC) pay a dividend?

When is NeuroOne Medical Tech (NASDAQ:NMTC) reporting earnings?

Is NeuroOne Medical Tech (NMTC) going to split?

What sector and industry does NeuroOne Medical Tech (NMTC) operate in?